Add like
Add dislike
Add to saved papers

Replacing Mancozeb with Alternative Fungicides for the Control of Late Blight in Potato.

Mancozeb (MZ) is a broadly used fungicide for the control of plant diseases, including late blight in potatoes caused by the oomycete Phytophthora infestans (Mont.) De Bary. MZ has been banned for agricultural use by the European Union as of January 2022 due to its hazards to humans and the environment. In a search for replacement fungicides, twenty-seven registered anti-oomycete fungicidal preparations were evaluated for their ability to mitigate the threat of this disease. Fourteen fungicides provided good control (≥75%) of late blight in potted potato and tomato plants in growth chambers. However, in Tunnel Experiment 1, only three fungicides provided effective control of P. infestans in potatoes: Cyazofamid (Ranman, a QiI inhibitor), Mandipropamid (Revus, a CAA inhibitor), and Oxathiapiprolin + Benthiavalicarb (Zorvek Endavia, an OSBP inhibitor + CAA inhibitor). In Tunnel Experiment 2, these three fungicides were applied at the recommended doses at 7-, 9-, and 21-day intervals, respectively, totaling 6, 4, and 2 sprays during the season. At 39 days post-inoculation (dpi), control efficacy increased in the following order: Zorvec Endavia > Ranman > Revus > Mancozeb. Two sprays of Zorvec Endavia were significantly more effective in controlling the blight than six sprays of Ranman or four sprays of Revus. We, therefore, recommend using these three fungicides as replacements for mancozeb for the control of late blight in potatoes. A spray program that alternates between these three fungicides may be effective in controlling the disease and also in avoiding the build-up of resistance in P. infestans to mandipropamid and oxathiapiprolin.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app